Cells
(Nov 2020)
Clinical Actionability of the Genomic Landscape of Metastatic Castration Resistant Prostate Cancer
Wout Devlies,
Markus Eckstein,
Alessia Cimadamore,
Gaëtan Devos,
Lisa Moris,
Thomas Van den Broeck,
Rodolfo Montironi,
Steven Joniau,
Frank Claessens,
Thomas Gevaert
Affiliations
Wout Devlies
Department of Urology, University Hospitals Leuven, 3000 Leuven, Belgium
Markus Eckstein
Department of Pathology, Friedrich-Alexander-University of Erlangen-Nürnberg, 91054 Erlangen, Germany
Alessia Cimadamore
Section of Pathological Anatomy, School of Medicine, Polytechnic University of the Marche Region, United Hospitals, 60121 Ancona, Italy
Gaëtan Devos
Department of Urology, University Hospitals Leuven, 3000 Leuven, Belgium
Lisa Moris
Department of Urology, University Hospitals Leuven, 3000 Leuven, Belgium
Thomas Van den Broeck
Department of Urology, University Hospitals Leuven, 3000 Leuven, Belgium
Rodolfo Montironi
Section of Pathological Anatomy, School of Medicine, Polytechnic University of the Marche Region, United Hospitals, 60121 Ancona, Italy
Steven Joniau
Department of Urology, University Hospitals Leuven, 3000 Leuven, Belgium
Frank Claessens
Laboratory of Molecular Endocrinology, KU Leuven, 3000 Leuven, Belgium
Thomas Gevaert
Department of Pathology, University Hospitals Leuven, 3000 Leuven, Belgium
DOI
https://doi.org/10.3390/cells9112494
Journal volume & issue
Vol. 9,
no. 11
Abstract
Read online
The development of targeted therapies increases treatment options for metastatic castration resistant prostate cancer (mCRPC) patients. There is a need for strong predictive and prognostic signatures to guide physicians in treating mCRPC patients. In this review we unravel the possible actionability in the AR pathway, PI3K AKT signaling, and DNA repair pathways. Additionally, we make recommendations on biomarker trial design, and the clinical use of this new type of data.
Keywords
WeChat QR code
Close
